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Summary
Objective: Invasive fungal infections are associated with high morbidity and increased mortality.
This study was performed to assess the epidemiology of fungal infections and to determine (1,3)-
b-D-glucan serum concentrations in patients admitted to intensive care units (ICUs).
Patients andmethods: Overall 197 patients were admitted to nine medical and surgical intensive
care units (ICUs) at a 2200-bed university hospital during a 3-month period. Retrospectively, the
patients were split into three groups: group A comprised 24 patients with proven invasive fungal
infections admitted for a median of 40 days. Group B comprised 58 patients who were admitted to
the ICU for 30 days but without fungal infection. One hundred and fifteen post-operative patients
served as controls (group C). The levels of (1,3)-b-D-glucan were monitored in all patients twice
weekly during their ICU admittance.
Results: Average (1,3)-b-D-glucan concentrations were significantly higher in the patients with
fungal infections compared to group B and group C (median 44 vs. 22 and 12.9 pg/ml, respec-
tively; p < 0.001). For a serum (1,3)-b-D-glucan level of 40 pg/ml, the sensitivity, the specificity,
the positive predictive value, the negative predictive value, the area under the curve of the
receiver operating characteristics (AUC ROC) curve, the likelihood ratio (LR)+ and LRwere 52.2,
75.9, 46.2, 80, 0.7, 2.16, and 0.63, respectively, on day 7. Patients in group A had bacterial
infections significantly more often than patients in group B ( p = 0.003). The hospitalization
before ICU admittance for group A was significantly longer than for groups B and C (median 19
(group A) vs. 6 (group B) vs. 10 (group C) days; p < 0.05).
* Corresponding author. Tel.: +43 1 40400 4440; fax: +43 1 40400 4418.
E-mail address: elisabeth.presterl@meduniwien.ac.at (E. Presterl).
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Conclusions: Longer hospitalization and multiple bacterial infections were found to be the main
risk factors for invasive fungal infections. Long-term ICU patients have elevated (1,3)-b-D-glucan
levels, not only due to invasive fungal infections, but also due to the serious underlying diseases
and conditions, inter-current complications, and intensive care measures. Yet, persistently high
serum levels of (1,3)-b-D-glucan in ICU patients may be indicative of invasive fungal infections and
warrant additional diagnostic efforts.
# 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Invasive fungal infections are of increasing relevance for
severely ill and immunocompromised patients. The attribu-
table mortality is up to 50%.1,2 Given the high mortality of
invasive infections, early and adequate treatment is vital.
Candida species are the predominant pathogens causing
invasive disease in intensive care, however invasive disease
caused by Aspergillus in non-neutropenic intensive care unit
(ICU) patients is increasing.3 The basic problem associated
with adequate treatment of fungal infections in ICU patients
is accurate diagnosis, with blood cultures being notoriously
insensitive. There have been intensive efforts to identify
markers of fungal invasion, including serological methods
to detect surface antigens, metabolites, or antibodies
against fungal antigens.4 Both, the sensitivity and specificity
of these methods are highly variable and depend on the
patients studied, but in short depend on the test and patient
population investigated.4 The (1,3)-b-D-glucan assay (which
is based on the recognition of (1,3)-b-D-glucan, a component
of the cell wall of Candida and Aspergillus, by the innate
immune system of horseshoe crabs5), was developed about 10
years ago. Given the limits of the present diagnostic arma-
mentarium, this test may be useful for the diagnosis of
invasive Candida and Aspergillus infections in ICU patients.
In this observational study, the clinical and epidemiolo-
gical data of patients admitted for 7 days to the ICU were
analyzed for the presence of invasive fungal infections. To
evaluate the usefulness of (1,3)-b-D-glucan levels in serum
for the detection of invasive fungal infections, and for inva-
sive Candida infection in particular, (1,3)-b-D-glucan concen-
trations were measured sequentially during the patients’
admittance to the ICU.
Methods
The study was conducted from February 2004 to April 2004.
Patients from nine intensive care units were enrolled, includ-
ing units of neurosurgery, trauma surgery, solid organ trans-
plantation, medical cardiology, cardiothoracic surgery, and
general abdominal surgery/anesthesiology. After 7 days of
admission in the ICU, patients were screened for the pre-
sence of invasive fungal infection using the Candida hemag-
glutination test. Patient sera were also tested for the
presence of (1,3)-b-D-glucan using the commercially avail-
able Glucatell test (Cape Cod, USA).
Patients
During the observation period, 197 patients were admitted to
the ICUs. The patients were retrospectively classified intothree groups based on the presence of an invasive fungal
infection and the length of admittance. Group A (N = 24)
included patients with severe underlying diseases, extensive
surgery and other underlying conditions, and a stay of at least
7 days. These patients had proven invasive fungal infections
with growth of fungi in blood cultures and abscesses or
aspirates from otherwise sterile compartments (pleura, cer-
ebrospinal fluid). All patients from group A received anti-
fungal treatment. Group B (N = 58) included patients with
severe underlying diseases and extensive surgery and other
underlying conditions, who were admitted to the ICU for at
least 7 days, but did not have evidence of fungal infection
based on the clinical and microbiological data. Group B
patients did not receive antifungal therapy. Group C
(N = 115) comprised post-operative patients without evi-
dence of fungal infection admitted to the ICUs for post-
operative monitoring for 7 days.
The following data were collected from the patient charts:
age, gender, underlying disease, reason for ICU admission,
concomitant infections, presence and duration of risk factors
for Candida colonization and infection, antifungal treatment,
and vital status at discharge (survival vs. death).
Microbiology and serology
Specimens for microbiological cultures were taken from per-
ipheral blood, aspirates of abscesses, intravascular lines,
wound exudates, surgical drains, or other infectious foci, if
clinically indicated. Specimens were processed at the clinical
microbiology laboratory for the detection of Candida accord-
ing to standard procedures. These included inoculating onto
ChromAgar (Becton & Dickinson, Germany) and processing of
blood cultures using an automated system (BacTAlert FA and
FN, BioMerieux, France). Identification of yeasts to the species
level was carried out using the API 32ID whenever possible.
During the 3-month period, blood samples for Candida
serology were collected twice weekly in endotoxin-free tubes
(Greiner) to avoid endotoxin contamination, and serum was
frozen at 72 8C and examined in bulk using the (1,3)-b-D-
glucan assay (Glucatell). The assay was performed according
to the protocol supplied by the manufacturer on the Internet
(2004). Two procedures can be used to measure the (1,3)-b-D-
glucan, the end-point assay and the kinetic rate assay, and in
this study we used the end-point assay. To detect Candida
antibodies the Candida hemagglutination test (Hemkit Can-
dida IHA, Ravo Diagnostika, Germany) was used. To ascertain
reproducibility of the tests, controls were run with each test.
Statistics
Significance of difference was assessed by means of the Chi-
square test for categorical variables and the Wilcoxon rank
serum (1,3)-b-D-glucan in ICU patients 709sum test for continuous variables. For subgroups and non-
normally distributed variables the Mann—Whitney U test was
used. All tests were two-sided, and p < 0.05 was considered
significant. The following indices of diagnostic performance
and their 95% confidence intervals (CI) were calculated:
sensitivity, specificity, the positive predictive value (PPV),
the negative predictive value (NPV), likelihood ratio test (LR)
positivity (LR+), and LR negativity (LR). LR+ and LR are
independent of prevalence, as are sensitivity and specificity,
and are therefore increasingly used to evaluate diagnostic
test performance. The predictive values of the LR+/LR are:
>10/ < 0.1 very good, 5—10/0.1—0.2 useful, 2—5/0.2—0.5
medium, and 1—2/0.5—1 negligible. The discriminatory
power of the (1,3)-b-D-glucan levels in serum was evaluated
by the area under the receiver operating characteristics (AUC
ROC) curve and the 95% CI. Descriptive and correlation
statistics were obtained using SPSS for Windows, release
13 (SPSS Inc., Chicago, USA).
Results
During the 3-month surveillance period, 24 patients with
invasive fungal infections (22 with Candida infections and
two with invasive aspergillosis; group A) and 58 patients
without fungal infection who were admitted to the ICU for
at least 7 days (group B) were identified. Group C consisted of
115 post-operative patients (71 males, 44 females) who had
undergone cardiac surgery (n = 29), abdominal surgery
(n = 40), orthopedic surgery (n = 19), or neurosurgery
(n = 27). Demographic data are given in Table 1. The overall
incidence of fungal infections during the 3-month surveil-
lance period was 12.2%.Table 1 Demography and predisposing conditions for invasive fu
Group A
Number of patients 24
Male/female 17/7
Overall mortality 6/24 (25%)
Temperature, median (range) 37.9 8C (35.3—40.1)
Admittance to ICU, median (range) 40 days (30—246)
Hospitalization before, median (range) 19 days (4—107)
Predisposing conditions for fungal infections
Immunsuppression 11
Hemodialysis 8
Surgery 19
Central venous catheter 23
Urinary catheter 21
Diarrhea 5
Parenteral nutrition 17
Endotracheal ventilation 22
Cutaneous candidiasis 2
Diabetes mellitus 5
Neutropenia 1
Cytotoxic chemotherapy 3
Radiation 3
Groups A and B, long-term ICU patients; group C, post-operative patients
95% confidence interval.Patients in group A had bacterial infections significantly
more often than patients in group B (22/24 patients in group
A vs. 30/58 patients in group B; p = 0.003; Table 2). Although
there was no difference in the number of patients receiving
broad-spectrum antimicrobial therapy (A, n = 24/24; B,
n = 37/58), group A received a significantly greater number
of different antimicrobial agents then group B (mean 3.8/
patient vs. 0.83/patient; p < 0.05). There was no difference
between group A and group B with regard to the underlying
diseases and predisposing conditions for invasive fungal
infections. The underlying diseases comprised primarily
trauma, cardiovascular disease, and organ transplantation
(Table 2). There was no significant difference in the incidence
of conditions considered risk factors for invasive fungal
infections (Table 1) between groups A and B.
In group A, the fungal infections comprised candidemia
(n = 11) and hepatic candidiasis (n = 9), Candida peritonitis
(n = 2), and invasive aspergillosis of the lung (n = 2). The
fungal pathogens were Candida albicans (n = 14), Candida
glabrata (n = 4), Candida tropicalis (n = 2), Candida krusei
(n = 2), and Aspergillus fumigatus (n = 2). All patients
received antifungal treatment comprising fluconazole
(n = 13), caspofungin (n = 6), amphotericin B (n = 4), and
voriconazole (n = 3). Three patients received a combination
with amphotericin B and caspofungin, and two patients
received fluconazole and caspofungin sequentially. Nine
patients died within 14 days after the onset of the fungal
infection and 15 patients (62%) survived.
The median (1,3)-b-D-glucan concentrations were signifi-
cantly higher in the group A patients with fungal infections
compared to group B and group C (median 44 vs. 22 and 12.9
pg/ml, respectively; p < 0.001) (Table 3). The (1,3)-b-D-
glucan concentrations remained significantly higher in groupngal infections
Group B Group C p-Value
58 115 -
39/19 71/44 NS
10/58 (17.2%) 3/115 (2.6%) 0.003
37.8 8C (36.1—40.3) 37.1 8C (35.7—38.9) NS
30 days (7—167) - NS
6 days (1—69) 10 days (1—66) 0.047
OR (95% CI)
14 2.66 (0.98—7.85)
13 1.7 (0.61—4.96)
46 0.99 (0.31—3.2)
50 3.68 (0.43—31.2)
50 1.12 (0.27—4.64)
6 2.28 (0.62—8.35)
34 2.97 (1.42—11.1)
46 2.87 (0.59—13.8)
3 2.87 (0.59—13.8)
5 2.79 (0.73—10.7)
2 1.2 (0.11—14.1)
2 4 (0.6—25.7)
2 4 (0.6—25.7)
; ICU, intensive care unit; NS, not significant; OR, odds ratio; 95% CI,
Table 2 Underlying diseases und infections in the long-term
intensive care unit patient groups A and B
Group A
(N = 24)
Group B
(N = 58)
Underlying diseases
Cardiovascular disease 3 7
Trauma 6 16
Acute respiratory distress syndrome 1 2
Solid neoplasm 5 5
AIDS 1 0
Past organ transplantation 0 2
Recent organ transplantation 5 10
Cerebral hemorrhage 2 12
Liver disease 2 9
Lung disease 4 4
Leukemia/lymphoma 2 1
Renal disease 0 1
Bacterial infections 22 30
Pneumonia 9 10
Septicemia 4 8
Osteomyelitis 3 3
Catheter-related bacteremia 3 1
Peritonitis 3 1
Urinary tract infection 3 1
Cholangitis 1 1
Abscess 2 1
Fasciitis 1 0
Wound infection 0 1
Abscess 1 0
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710 E. Presterl et al.A than in group B over 7—10 days, but then decreased to a
similar level (Table 3, Figure 1). For a serum (1,3)-b-D-glucan
level of 40 pg/ml, the sensitivity, the specificity, the positive
predictive value, and the negative predictive value of the
(1,3)-b-D-glucan assay used were 52.2, 75.9, 46.2, and 80%,
respectively, on day 7 after admission to the ICU. The
descriptive parameters for the efficiency of (1,3)-b-D-glucan
levels 40 pg/ml to detect a fungal infection are given in
Table 3. The LR+ ranged from 2.16 to 3.09, the LR, however,
was persistently greater than 0.5. On days 7, 10, and 14, the
AUC ROC curve was greater than 0.7 indicating an acceptable
association of increasing (1,3)-b-D-glucan serum levels with
the presence of invasive fungal infection ( p = 0.005).
On day 7, 14 patients from group B (without fungal
infections) had (1,3)-b-D-glucan levels 40 pg/ml: six
patients had concurrent bacterial infections including pneu-
monia (n = 2; Streptococcus pneumoniae, Staphylococcus
aureus), osteomyelitis (S. aureus), peritonitis, and cathe-
ter-associated bacteremia (n = 2; Staphylococcus epidermi-
dis). The (1,3)-b-D-glucan levels were not persistent, and by
day 14, eight other patients from group B had (1,3)-b-D-
glucan levels 40 pg/ml. Two of these patients had cathe-
ter-associated bacteremia with S. epidermidis. In one
patient, Pneumocystis jirovecii pneumonia was suspected
and treated after the study. The other patients had no proven
bacterial infections. All of these patients had central venous
catheters and various other invasive ICU devices and gear.
With regard to the Candida hemagglutination titer, there
was no difference between the three patient groups on day 7
Figure 1 Mean concentrations of (1,3)-b-D-glucan over time
(squares: group A, patients with fungal infections; circles: group
B, patients without fungal infections).
serum (1,3)-b-D-glucan in ICU patients 711(group A: 0 (0—20 480); group B: 0 (0—2560); group C 0 (0—
10 240); median (range)) and between the two long-term ICU
patient groups A and B on days 10, 14, and 17 [group A: day
10, 0 (0—1280); day 14, 0 (0—1280); day 17, 0 (0—1280);
group B: day 10, 0 (0—2560); day 14, 0 (0—2560); day 17, 0
(0—2560); median (range)].
Discussion
Compared to most studies evaluating (1,3)-b-D-glucan levels
at the time of infection only, the present study has docu-
mented the course of (1,3)-b-D-glucan levels in a ‘normal’,
heterogeneous ICU population during the period of their
admittance using the (1,3)-b-D-glucan research test. At 7
days post-admission, patients with acute invasive Candida
infections had significantly higher serum concentrations of
(1,3)-b-D-glucan than patients without fungal infections or
the short-term ICU patients. In patients with fungal infec-
tions the (1,3)-b-D-glucan levels were persistently high, and
decreased slowly (Figure 1). However, (1,3)-b-D-glucan levels
of long-term ICU patients without fungal infections also
increased starting at day 14, but importantly not to serum
levels detected in patients with proven fungal infections
(Figure 1). There may be several explanations: Elevated
concentrations of (1,3)-b-D-glucan have been reported to
be associated with Gram-positive infections, biofilms on
vascular catheters, hemodialysis, or the administration of
intravenous immunoglobulins.6—8 Out of the long-term ICU
patients without fungal infections, five had hemofiltration,
another five had Gram-positive infections due to S. aureus or
S. pneumoniae, and four patients had catheter-associated
bacteremia due to coagulase-negative staphylococci. None
of them received immunoglobulins. After the end of the
study, a patient was treated for Pneumocystis pneumonia
suspected because of his underlying immunodeficiency syn-
drome. Only recently, Persat et al. described the usefulness
of determining (1,3)-b-D-glucan in the diagnosis of Pneumo-
cystis pneumonia patients.9 These interactions may haveinfluenced the sensitivity, specificity, PPV, NPV, LR+, and
LR. Moreover, Candida colonization and occult candidemia
cannot be totally excluded however evaluation of Candida
colonization was not systematically performed or documen-
ted limiting the information obtained in a retrospective
study.
The diagnosis of invasive Candida infections in ICU
patients is still an enigma. Scores to quantitate Candida
colonization for the decision to start antifungal treatment
at the bedside may be helpful, but are inaccurate tools for
the diagnosis of invasive Candida infection.10,11 Methods
under investigation for the diagnosis of invasive fungal infec-
tions involve the detection of fungal antigens or metabolites,
or PCR-based assays.4,12 However, assays for Candida meta-
bolites, mannan and enolase, and antibodies against Candida
have never proved to be fully diagnostic for the invasive
Candida infection.13—15 Increased (1,3)-b-D-glucan serum
levels have been reported to be very useful in the diagnosis
of experimental candidiasis and various fungal infections in
humans.16,17 The study of Digby et al. comparing a small
number of patients with Candida infection and patients with
bacterial infections, described a low specificity of the (1,3)-
b-D-glucan assay.6 However, in patients with hematological
malignancies and transplant recipients, monitoring of (1,3)-
b-D-glucan antigenemia may be a useful method for the early
diagnosis of invasive fungal infections including even asper-
gillosis.18,19,8
The patient population admitted at these ICUs was rather
heterogeneous. The high incidence of fungal infections in
almost one third of the long-term ICU patients may be
explained by the long pre-ICU admittance of the patients
and serious underlying diseases necessitating ICU stays of up
to 246 days. For early diagnosis of invasive fungal infections,
additional non-invasive methods may be useful. But this
study highlights the difficulties in the interpretation of
increased (1,3)-b-D-glucan levels and the importance of
evaluating this serological method in the ICU patient popula-
tion. In high-risk ICU patients, when results of cultures of
blood or sterile body sites are still pending or negative, high
serum concentrations of (1,3)-b-D-glucan may be another
useful piece of evidence in the diagnosis of invasive fungal
infections.
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